TScan Therapeutics Inc. (TCRX)
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
📈 **POSITIVE** • Medium confidence analysis (68%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business